/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-04-29 22:07:362018-01-04 22:07:55Avita Medical – Shareholder Letter
NZX / MEDIA RELEASE 26 April 2016. Link here. Omega-3 update; Omega-2 sales slow; Revised financial guidance SeaDragon Limited (NZX:SEA) is pleased to update the market on the following recent events. Omega-3 Refinery As previously noted to the market, the commissioning of SeaDragon’s new Omega-3 refinery has been successfully completed, with the plant meeting performance […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-04-22 22:08:092018-01-06 19:35:29AVH – International Experts Honoured with Awards at 4th Annual Skin Regeneration Symposium
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-04-21 22:09:092018-01-05 19:42:39ADR – EDISON RESEARCH INITIATES COVERAGE OF ADHERIUM
SAN DIEGO, April 20, 2016– Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing first-in-man Phase I clinical trial for chronic rhinosinusitis patients treated with AmpliPhi’s proprietary phage cocktail AB-SA01. The first cohort, […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-04-20 22:08:382019-02-13 12:51:57AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
Extensive burns research data presented at Skin Regeneration Symposium in Cambridge, UK. – ReCell technology improves burn wound healing, reduces scarring, discoloration and itching – ReCell effective for extreme burns in emergency situations – 95% healing in less than 2 months achieved with ReCell for explosion patient with 70% burn – Leading EU hospital incorporating […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-04-19 22:11:462018-01-04 22:12:14Skin Regeneration Technology Critical to Recovery and Quality of Life in Burns Patients Say Top Clinicians
SAN DIEGO, April 14, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon. Under the terms of the agreement, AmpliPhi has the […]
SAN DIEGO, April 12, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix […]
Avita Medical – Shareholder Letter
/in Portfolio Companies29 April, 2016. Link here.
SeaDragon – Market Update
/in Portfolio Companies, SeaDragonNZX / MEDIA RELEASE 26 April 2016. Link here. Omega-3 update; Omega-2 sales slow; Revised financial guidance SeaDragon Limited (NZX:SEA) is pleased to update the market on the following recent events. Omega-3 Refinery As previously noted to the market, the commissioning of SeaDragon’s new Omega-3 refinery has been successfully completed, with the plant meeting performance […]
AVH – International Experts Honoured with Awards at 4th Annual Skin Regeneration Symposium
/in Avita Medical, Portfolio CompaniesApril 22, 2016. Link here.
AVH – ReNovaCell™ Skin Regeneration Technology Improves Pigmentation and Appearance of Scars
/in Portfolio CompaniesAesthetics data presented at Skin Regeneration Symposium in Cambridge, UK. 21 April 2016. Link here.
ADR – EDISON RESEARCH INITIATES COVERAGE OF ADHERIUM
/in Adherium, Portfolio CompaniesMelbourne, Australia, 21 April 2016. Link here.
AVH – ReGenerCell Skin Regeneration Technology Decreases Size and Pain in Chronic Wounds
/in Portfolio CompaniesChronic Wounds Data Presented at Skin Regeneration Symposium in Cambridge, UK. Cambridge, United Kingdom, 20 April 2016. Link here.
AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
/in Armata PharmaceuticalsSAN DIEGO, April 20, 2016– Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing first-in-man Phase I clinical trial for chronic rhinosinusitis patients treated with AmpliPhi’s proprietary phage cocktail AB-SA01. The first cohort, […]
Skin Regeneration Technology Critical to Recovery and Quality of Life in Burns Patients Say Top Clinicians
/in Portfolio CompaniesExtensive burns research data presented at Skin Regeneration Symposium in Cambridge, UK. – ReCell technology improves burn wound healing, reduces scarring, discoloration and itching – ReCell effective for extreme burns in emergency situations – 95% healing in less than 2 months achieved with ReCell for explosion patient with 70% burn – Leading EU hospital incorporating […]
AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon
/in Armata Pharmaceuticals, Portfolio CompaniesSAN DIEGO, April 14, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon. Under the terms of the agreement, AmpliPhi has the […]
AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients
/in Portfolio CompaniesSAN DIEGO, April 12, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix […]